Evaluation of Fecal Microbiome Changes After Antegrade Continence Enema Placement and Initiation of Bowel Flush Regimen
Indiana University · NCT05821309
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 2–18 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Phase 4
- Target enrollment
- 65
- US sites recruiting
- 2
- Study start
- June 8, 2023
- Record last updated
- August 18, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This study will evaluate changes in the fecal microbiome in constipated pediatric patients before and after antegrade continence enema placement and initiation of antegrade enema flushes. Subjects will have their microbiome sequenced prior to placement by obtaining a fecal sample. Pre-antegrade continence enema placement results will be compared to fecal samples obtained at 0, 4, 8 months after placement of the antegrade continence enema and initiation of miralax or golytely flushes to look for changes in bacterial diversity.
Being studied: PEG 3350; PEG-3350 with electrolytes; Glycerin
Conditions: Constipation
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Recalcitrant chronic functional constipation necessitating a MACE appendicostomy or cecostomy for treatment at Riley Hospital for Children
- Intact colonic motility as evidenced by CMS studies
Exclusion Criteria
- Underlying anatomic or pathologic etiology for constipation
- History of prior gastrointestinal surgery (excluding placement of G or GJ tubes)
- Underlying severe GI disease unrelated to the patient's chronic constipation
- Use within the past month of consent of probiotic supplements, prebiotic supplements or antibiotics
Recruiting US locations
IU North Hospital
Carmel, IN 46032
Site contact: Erik Andrewski, MD · 317-944-3774 · edandrew@iu.edu
Riley Hospital for Children
Indianapolis, IN 46224
Site contact: Erik Andrewski, MD · 317-944-3774 · edandrew@iupui.edu
Study contacts (from the official record)
- Erik Andrewski, MD · 317-944-3774 · edandrew@iupui.edu
- Ann Klipsch, RN · 317-944-3774 · aeye@iu.edu
Similar studies in Indiana
All healthy volunteers studies in Indiana →- RecruitingHealthy volunteersEarly Phase 1Overnight stay mentioned
Interaction of CYP2B6 Genotype and Efavirenz With Methadone and Tizanidine PK
Indiana University
- Location
- Indianapolis, IN
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteersPhase 1
Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
Arcutis Biotherapeutics, Inc.
- Location
- Plainfield, IN + 6 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteersPhase 1/Phase 2
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older
Sanofi
- Location
- Indianapolis, IN + 49 other US sites
- Eligibility basics
- Ages 60+
- RecruitingHealthy volunteersPhase 1/Phase 2
Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)
Atavistik Bio, Inc
- Location
- Indianapolis, IN + 5 other US sites
- Eligibility basics
- Ages 18+